Literature DB >> 24177041

Does lemon juice increase radioiodine reaccumulation within the parotid glands more than if lemon juice is not administered?

Kanchan Kulkarni1, Douglas Van Nostrand, Francis Atkins, Mihriye Mete, Jason Wexler, Leonard Wartofsky.   

Abstract

OBJECTIVE: The protective effect of sialagogues following I therapy became controversial after a study proposed that sialagogues increase the reaccumulation of I in the parotid glands (PGs) to a level higher than when sialagogues are not administered ('rebound effect'). The present study examined PG radiopharmacokinetics within 2-4 h after radioiodine administration to evaluate whether sialagogues cause a 'rebound effect'. PATIENTS AND METHODS: This prospective study was conducted at the Medstar Washington Hospital Center. The study patients had (i) differentiated thyroid cancer, (ii) no history of salivary gland disease or medications affecting the salivary glands, (iii) a clinical salivary scan (SS) with lemon juice (LJ) (SSwLJ) that was performed before I therapy, and (iv) a second SS performed without LJ (SSwoLJ) performed prior to I therapy after giving informed consent. Each PG was assessed for I uptake using time-activity curves (TACs) that were (i) corrected for background and decay, (ii) smoothed using a seven-point unweighted moving average, and (iii) normalized to the administered I activity. TACs of the SSwLJ and SSwoLJ were compared with activity at each time point over 120 min. Areas under the TACs for the PGs were calculated for each gland's SSwLJ and SSwoLJ, and the relative percentage change in potential radiation absorbed dose (PRAD) was calculated.
RESULTS: A total of 2100 time points were analyzed in nine patients (18 PGs). I activity in the PGs on SSwLJ exceeded activity seen on the SSwoLJ at 134 time points (6.3%), and 98 (73%) of these were on the basis of spontaneous salivation during SSwoLJ. Mean percentage decrease in relative PRAD was 34.2±17.4% (range, 3.1-66.1%).
CONCLUSION: During the time period studied, LJ administration did not result in a 'rebound effect' but resulted in mean relative decrease of 34.2% in PRAD to the PGs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24177041     DOI: 10.1097/MNM.0000000000000034

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  10 in total

Review 1.  Radioiodine Treatment and Thyroid Hormone Suppression Therapy for Differentiated Thyroid Carcinoma: Adverse Effects Support the Trend toward Less Aggressive Treatment for Low-Risk Patients.

Authors:  E N Klein Hesselink; T P Links
Journal:  Eur Thyroid J       Date:  2015-06-11

2.  Sublingual Atropine Administration as a Tool to Decrease Salivary Glands' PSMA-Ligand Uptake: A Preclinical Proof of Concept Study Using [68Ga]Ga-PSMA-11.

Authors:  Vincent Nail; Béatrice Louis; Anaïs Moyon; Adrien Chabert; Laure Balasse; Samantha Fernandez; Guillaume Hache; Philippe Garrigue; David Taïeb; Benjamin Guillet
Journal:  Pharmaceutics       Date:  2022-06-16       Impact factor: 6.525

3.  Salivary Function after Radioiodine Therapy: Poor Correlation between Symptoms and Salivary Scintigraphy.

Authors:  Jacqueline Jonklaas; Hong Wang; Giuseppe Esposito
Journal:  Front Endocrinol (Lausanne)       Date:  2015-06-17       Impact factor: 5.555

4.  PSMA PET/CT Identifies Intrapatient Variation in Salivary Gland Toxicity From Iodine-131 Therapy.

Authors:  Vineet Mohan; Wouter V Vogel; Gerlof D Valk; Jan P de Boer; Marnix G E H Lam; Bart de Keizer
Journal:  Mol Imaging       Date:  2020 Jan-Dec       Impact factor: 4.488

5.  Muscarinic inhibition of salivary glands with glycopyrronium bromide does not reduce the uptake of PSMA-ligands or radioiodine.

Authors:  V Mohan; N M Bruin; M E T Tesselaar; J P de Boer; E Vegt; J J M A Hendrikx; A Al-Mamgani; J B van de Kamer; J-J Sonke; W V Vogel
Journal:  EJNMMI Res       Date:  2021-03-12       Impact factor: 3.138

Review 6.  Strategies for Radioiodine Treatment: What's New.

Authors:  Clotilde Sparano; Sophie Moog; Julien Hadoux; Corinne Dupuy; Abir Al Ghuzlan; Ingrid Breuskin; Joanne Guerlain; Dana Hartl; Eric Baudin; Livia Lamartina
Journal:  Cancers (Basel)       Date:  2022-08-04       Impact factor: 6.575

7.  Optimal administration time of vitamin C after 131I therapy in differentiated thyroid cancer based on propensity score matching.

Authors:  Ye Liu; Yuhua Wang; Wanchun Zhang
Journal:  Front Surg       Date:  2022-09-22

Review 8.  Sialadenitis as a complication of radioiodine therapy in patients with thyroid cancer: where do we stand?

Authors:  Marios Adramerinas; Dimitrios Andreadis; Konstantinos Vahtsevanos; Athanasios Poulopoulos; Kalliopi Pazaitou-Panayiotou
Journal:  Hormones (Athens)       Date:  2021-06-18       Impact factor: 2.885

Review 9.  Clinical Studies of Nonpharmacological Methods to Minimize Salivary Gland Damage after Radioiodine Therapy of Differentiated Thyroid Carcinoma: Systematic Review.

Authors:  Andri Christou; Evridiki Papastavrou; Anastasios Merkouris; Savvas Frangos; Panayiota Tamana; Andreas Charalambous
Journal:  Evid Based Complement Alternat Med       Date:  2016-06-30       Impact factor: 2.629

Review 10.  Seeking Optimal Management for Radioactive Iodine Therapy-induced Adverse Effects.

Authors:  Andreas Charalambous
Journal:  Asia Pac J Oncol Nurs       Date:  2017 Oct-Dec
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.